These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 36769825)

  • 21. Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis.
    Cai J; Cui L; Wang Y; Li Y; Zhang X; Shi Y
    Front Pharmacol; 2021; 12():774808. PubMed ID: 34803716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond the Skin Plaques: Psoriasis and Its Cardiovascular Comorbidities.
    Kakarala CL; Hassan M; Belavadi R; Gudigopuram SVR; Raguthu CC; Gajjela H; Kela I; Sange I
    Cureus; 2021 Nov; 13(11):e19679. PubMed ID: 34976467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review.
    Kamata M; Tada Y
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32121574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of psoriasis as a systemic disease: what is the evidence?
    Korman NJ
    Br J Dermatol; 2020 Apr; 182(4):840-848. PubMed ID: 31225638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways.
    Piaserico S; Orlando G; Messina F
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges.
    Pannu S; Rosmarin D
    Am J Clin Dermatol; 2021 May; 22(3):293-300. PubMed ID: 33586126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies.
    Driessen RJ; Boezeman JB; Van De Kerkhof PC; De Jong EM
    J Dermatolog Treat; 2009; 20(1):42-7. PubMed ID: 18649164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular risk in psoriatic arthritis, a narrative review.
    Verhoeven F; Prati C; Demougeot C; Wendling D
    Joint Bone Spine; 2020 Oct; 87(5):413-418. PubMed ID: 31958573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of Metabolic Syndrome in Chinese Patients With Erythrodermic Psoriasis: A Case-Control Study.
    Ma AR; Liu F; Wang R; Lin L; Wang Y; Li Q; Lu X; Du J
    Front Endocrinol (Lausanne); 2021; 12():677912. PubMed ID: 34970217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Effects of Biologics on Renal Function in Psoriatic Patients: A Retrospective Study.
    Chen CB; Huang YT; Hsiao CC; Chang SH; Chi CC
    BioDrugs; 2022 Sep; 36(5):657-666. PubMed ID: 35994233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis.
    Shapiro J; Cohen AD; Weitzman D; Tal R; David M
    J Am Acad Dermatol; 2012 Feb; 66(2):252-8. PubMed ID: 21742411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psoriasis: comorbidities and associations.
    Farley E; Menter A
    G Ital Dermatol Venereol; 2011 Feb; 146(1):9-15. PubMed ID: 21317853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiometabolic Disorders in Psoriatic Disease.
    Sobchak C; Eder L
    Curr Rheumatol Rep; 2017 Aug; 19(10):63. PubMed ID: 28844116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease.
    Barbieri JS; Beidas RS; Gondo GC; Fishman J; Williams NJ; Armstrong AW; Ogdie AR; Mehta N; Gelfand JM
    JAMA Dermatol; 2022 Mar; 158(3):252-259. PubMed ID: 35044419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psoriasis and its comorbidities.
    Onumah N; Kircik LH
    J Drugs Dermatol; 2012 May; 11(5 Suppl):s5-10. PubMed ID: 22644770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psoriasis and atherosclerosis: Is there a need for novel biomarkers assessing cardiovascular risk?
    Sunbul M; Agirbasli M
    Curr Pharm Des; 2014; 20(4):529-35. PubMed ID: 23565636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidized Lipids and Lipoprotein Dysfunction in Psoriasis.
    Sorokin AV; Remaley AT; Mehta NN
    J Psoriasis Psoriatic Arthritis; 2020 Oct; 5(4):139-146. PubMed ID: 33163854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study.
    Belinchón I; Vanaclocha F; de la Cueva-Dobao P; Coto-Segura P; Labandeira J; Herranz P; Taberner R; Juliá B; Cea-Calvo L; Puig L
    J Dermatolog Treat; 2015; 26(4):318-25. PubMed ID: 25362972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary care-based screening for cardiovascular risk factors in patients with psoriasis.
    Rutter MK; Kane K; Lunt M; Cordingley L; Littlewood A; Young HS; Chew-Graham CA; Hilton R; Symmons DP; Griffiths CE
    Br J Dermatol; 2016 Aug; 175(2):348-56. PubMed ID: 26990294
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.